Association of the blood eosinophil count with hematological malignancies and mortality

Christen L. Andersen, Volkert D. Siersma, Hans C. Hasselbalch, Hanne Vestergaard, Ruben Mesa, Peter Felding, Niels D F Olivarius, Ole W. Bjerrum

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Blood eosinophilia (≥0.5 × 109/l) may be an early sign of hematological malignancy. We investigated associations between levels of blood eosinophils and risks of hematological malignancies and mortality in order to provide clinically derived cut-offs for referral to specialist hematology care. From the Copenhagen Primary Care Differential Count (CopDiff) Database, we identified 356,196 individuals with at least one differential cell count encompassing the eosinophil count during 2000-2007 and matched these laboratory data with Danish nationwide health registers. We used multivariable logistic regression to calculate odds ratios (ORs) for the 4-year incidences of hematological malignancies and mortality between the eosinophil counts and a reference count of 0.16 × 109/l which was the median eosinophil count in our data. Risks of hematological malignancies and mortality increased above the median eosinophil count. At the 99th percentile, corresponding to an eosinophil count of 0.75 × 109/l, risks of hematological malignancies were increased more than twofold with OR (95% C.I.) of 2.39 (1.91-2.99). Interestingly, risks reached a plateau around an eosinophil count of 1.0 × 109/l. Risks also increased when the eosinophil count approached zero. Here, counts associated relatively more with acute myeloid leukemia and myelodysplastic syndromes whereas counts above 0.16 × 109/l associated more with myeloproliferative neoplasms. Eosinophil counts associate with hematological malignancies and mortality even below the definition of eosinophilia. The observed plateau of risks around 1.0 × 109/l is important for physicians encountering patients with eosinophilia since even mild-to-moderate eosinophilia according to traditional definitions confers maximally increased risks of subsequent/subclinical hematological malignancy.

Original languageEnglish (US)
Pages (from-to)225-229
Number of pages5
JournalAmerican Journal of Hematology
Volume90
Issue number3
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Hematologic Neoplasms
Eosinophils
Mortality
Eosinophilia
Odds Ratio
Myelodysplastic Syndromes
Hematology
Acute Myeloid Leukemia
Primary Health Care
Referral and Consultation
Cell Count
Logistic Models
Databases
Physicians
Incidence
Health

ASJC Scopus subject areas

  • Hematology

Cite this

Andersen, C. L., Siersma, V. D., Hasselbalch, H. C., Vestergaard, H., Mesa, R., Felding, P., ... Bjerrum, O. W. (2015). Association of the blood eosinophil count with hematological malignancies and mortality. American Journal of Hematology, 90(3), 225-229. https://doi.org/10.1002/ajh.23916

Association of the blood eosinophil count with hematological malignancies and mortality. / Andersen, Christen L.; Siersma, Volkert D.; Hasselbalch, Hans C.; Vestergaard, Hanne; Mesa, Ruben; Felding, Peter; Olivarius, Niels D F; Bjerrum, Ole W.

In: American Journal of Hematology, Vol. 90, No. 3, 01.01.2015, p. 225-229.

Research output: Contribution to journalArticle

Andersen, CL, Siersma, VD, Hasselbalch, HC, Vestergaard, H, Mesa, R, Felding, P, Olivarius, NDF & Bjerrum, OW 2015, 'Association of the blood eosinophil count with hematological malignancies and mortality', American Journal of Hematology, vol. 90, no. 3, pp. 225-229. https://doi.org/10.1002/ajh.23916
Andersen, Christen L. ; Siersma, Volkert D. ; Hasselbalch, Hans C. ; Vestergaard, Hanne ; Mesa, Ruben ; Felding, Peter ; Olivarius, Niels D F ; Bjerrum, Ole W. / Association of the blood eosinophil count with hematological malignancies and mortality. In: American Journal of Hematology. 2015 ; Vol. 90, No. 3. pp. 225-229.
@article{a1c23cb1446843f0a06a9fb446a29981,
title = "Association of the blood eosinophil count with hematological malignancies and mortality",
abstract = "Blood eosinophilia (≥0.5 × 109/l) may be an early sign of hematological malignancy. We investigated associations between levels of blood eosinophils and risks of hematological malignancies and mortality in order to provide clinically derived cut-offs for referral to specialist hematology care. From the Copenhagen Primary Care Differential Count (CopDiff) Database, we identified 356,196 individuals with at least one differential cell count encompassing the eosinophil count during 2000-2007 and matched these laboratory data with Danish nationwide health registers. We used multivariable logistic regression to calculate odds ratios (ORs) for the 4-year incidences of hematological malignancies and mortality between the eosinophil counts and a reference count of 0.16 × 109/l which was the median eosinophil count in our data. Risks of hematological malignancies and mortality increased above the median eosinophil count. At the 99th percentile, corresponding to an eosinophil count of 0.75 × 109/l, risks of hematological malignancies were increased more than twofold with OR (95{\%} C.I.) of 2.39 (1.91-2.99). Interestingly, risks reached a plateau around an eosinophil count of 1.0 × 109/l. Risks also increased when the eosinophil count approached zero. Here, counts associated relatively more with acute myeloid leukemia and myelodysplastic syndromes whereas counts above 0.16 × 109/l associated more with myeloproliferative neoplasms. Eosinophil counts associate with hematological malignancies and mortality even below the definition of eosinophilia. The observed plateau of risks around 1.0 × 109/l is important for physicians encountering patients with eosinophilia since even mild-to-moderate eosinophilia according to traditional definitions confers maximally increased risks of subsequent/subclinical hematological malignancy.",
author = "Andersen, {Christen L.} and Siersma, {Volkert D.} and Hasselbalch, {Hans C.} and Hanne Vestergaard and Ruben Mesa and Peter Felding and Olivarius, {Niels D F} and Bjerrum, {Ole W.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1002/ajh.23916",
language = "English (US)",
volume = "90",
pages = "225--229",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Association of the blood eosinophil count with hematological malignancies and mortality

AU - Andersen, Christen L.

AU - Siersma, Volkert D.

AU - Hasselbalch, Hans C.

AU - Vestergaard, Hanne

AU - Mesa, Ruben

AU - Felding, Peter

AU - Olivarius, Niels D F

AU - Bjerrum, Ole W.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Blood eosinophilia (≥0.5 × 109/l) may be an early sign of hematological malignancy. We investigated associations between levels of blood eosinophils and risks of hematological malignancies and mortality in order to provide clinically derived cut-offs for referral to specialist hematology care. From the Copenhagen Primary Care Differential Count (CopDiff) Database, we identified 356,196 individuals with at least one differential cell count encompassing the eosinophil count during 2000-2007 and matched these laboratory data with Danish nationwide health registers. We used multivariable logistic regression to calculate odds ratios (ORs) for the 4-year incidences of hematological malignancies and mortality between the eosinophil counts and a reference count of 0.16 × 109/l which was the median eosinophil count in our data. Risks of hematological malignancies and mortality increased above the median eosinophil count. At the 99th percentile, corresponding to an eosinophil count of 0.75 × 109/l, risks of hematological malignancies were increased more than twofold with OR (95% C.I.) of 2.39 (1.91-2.99). Interestingly, risks reached a plateau around an eosinophil count of 1.0 × 109/l. Risks also increased when the eosinophil count approached zero. Here, counts associated relatively more with acute myeloid leukemia and myelodysplastic syndromes whereas counts above 0.16 × 109/l associated more with myeloproliferative neoplasms. Eosinophil counts associate with hematological malignancies and mortality even below the definition of eosinophilia. The observed plateau of risks around 1.0 × 109/l is important for physicians encountering patients with eosinophilia since even mild-to-moderate eosinophilia according to traditional definitions confers maximally increased risks of subsequent/subclinical hematological malignancy.

AB - Blood eosinophilia (≥0.5 × 109/l) may be an early sign of hematological malignancy. We investigated associations between levels of blood eosinophils and risks of hematological malignancies and mortality in order to provide clinically derived cut-offs for referral to specialist hematology care. From the Copenhagen Primary Care Differential Count (CopDiff) Database, we identified 356,196 individuals with at least one differential cell count encompassing the eosinophil count during 2000-2007 and matched these laboratory data with Danish nationwide health registers. We used multivariable logistic regression to calculate odds ratios (ORs) for the 4-year incidences of hematological malignancies and mortality between the eosinophil counts and a reference count of 0.16 × 109/l which was the median eosinophil count in our data. Risks of hematological malignancies and mortality increased above the median eosinophil count. At the 99th percentile, corresponding to an eosinophil count of 0.75 × 109/l, risks of hematological malignancies were increased more than twofold with OR (95% C.I.) of 2.39 (1.91-2.99). Interestingly, risks reached a plateau around an eosinophil count of 1.0 × 109/l. Risks also increased when the eosinophil count approached zero. Here, counts associated relatively more with acute myeloid leukemia and myelodysplastic syndromes whereas counts above 0.16 × 109/l associated more with myeloproliferative neoplasms. Eosinophil counts associate with hematological malignancies and mortality even below the definition of eosinophilia. The observed plateau of risks around 1.0 × 109/l is important for physicians encountering patients with eosinophilia since even mild-to-moderate eosinophilia according to traditional definitions confers maximally increased risks of subsequent/subclinical hematological malignancy.

UR - http://www.scopus.com/inward/record.url?scp=84923071005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923071005&partnerID=8YFLogxK

U2 - 10.1002/ajh.23916

DO - 10.1002/ajh.23916

M3 - Article

C2 - 25488524

AN - SCOPUS:84923071005

VL - 90

SP - 225

EP - 229

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 3

ER -